We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

33 hedge funds and large institutions have $3.24M invested in Theriva Biologics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

0.01% more ownership

Funds ownership: 0.02% → 0.04% (+0.01%)

3% less capital invested

Capital invested by funds: $3.32M → $3.24M (-$86K)

3% less funds holding

Funds holding: 34 → 33 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
33
Holders Change
-1
Holders Change %
-2.94%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.22M
2
Truist Financial
Truist Financial
North Carolina
+$415K
3
Citadel Advisors
Citadel Advisors
Florida
+$88.4K
4
MP
MSD Partners
New York
+$87.8K
5
VF
Virtu Financial
New York
+$52.5K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$126K
2
Two Sigma Investments
Two Sigma Investments
New York
-$48.7K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$10K
4
CWA
Clearview Wealth Advisors
Oregon
-$9K
5
Mercer Global Advisors
Mercer Global Advisors
Colorado
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.43M +$1.22M +12,935 +161%
BlackRock
2
BlackRock
New York
$513K +$3.3K +35 +0.5%
Truist Financial
3
Truist Financial
North Carolina
$299K +$415K +4,400 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$265K – – –
State Street
5
State Street
Massachusetts
$128K – – –
MP
6
MSD Partners
New York
$96K +$87.8K +931 +200%
VF
7
Virtu Financial
New York
$90K +$52.5K +557 +72%
Citadel Advisors
8
Citadel Advisors
Florida
$76K +$88.4K +937 +535%
Northern Trust
9
Northern Trust
Illinois
$67K – – –
William Blair & Company
10
William Blair & Company
Illinois
$59K +$4.62K +49 +6%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$45K +$13.7K +145 +28%
Fisher Asset Management
12
Fisher Asset Management
Washington
$34K – – –
UBS Group
13
UBS Group
Switzerland
$26K +$17K +180 +86%
Two Sigma Investments
14
Two Sigma Investments
New York
$23K -$48.7K -516 -61%
BCM
15
Bridgeway Capital Management
Texas
$20K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$16K +$17.4K +184 +347%
SCM
17
Sterneck Capital Management
Missouri
$7K – – –
LFA
18
Landmark Financial Advisors
Kentucky
$7K +$9.15K +97 New
Morgan Stanley
19
Morgan Stanley
New York
$6K – – –
Renaissance Technologies
20
Renaissance Technologies
New York
$6K +$7.73K +82 New
Victory Capital Management
21
Victory Capital Management
Texas
$5K -$189 -2 -3%
JCM
22
Jacobi Capital Management
Pennsylvania
$5K – – –
IA
23
IFP Advisors
Florida
$5K +$3.77K +40 +267%
BSW
24
Buckingham Strategic Wealth
Missouri
$5K +$6.6K +70 New
Creative Planning
25
Creative Planning
Kansas
$3K – – –
1
2

TOVX Hedge Fund Activity: Q4 2021 in Review

33 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2021, worth a combined $3.24M — down 2.6% from $3.32M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TOVX and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 11 added.

The largest buyer was Vanguard Group, adding an estimated $1.22M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $126K sold.

  • 33 institutional investors held Theriva Biologics (TOVX) as of Q4 2021, down from 34 in Q3 2021.
  • Funds reported $3.24M of Theriva Biologics stock for Q4 2021, down 2.6% quarter-over-quarter.
  • 5 funds opened new Theriva Biologics positions in Q4 2021 and 6 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q4 2021 was Vanguard Group, an estimated $1.22M added.
  • The largest Theriva Biologics seller in Q4 2021 was GSA Capital Partners, an estimated $126K sold.

Based on aggregated 13F filings for Q4 2021.